Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease

NCT ID: NCT02859675

Last Updated: 2024-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-07

Study Completion Date

2021-05-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will improve our understanding of the mechanisms underlying anorexia in persons with Crohn's disease flare-ups. The practical spin-off from this research is potentially very important for the management of nutritional disorders associated with the disease by guiding diets towards foods that correspond to patients' preferences and/or to modified tastes. In addition, the results could lead to the identification of sensory markers that herald an inflammatory flare-up of the disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease Olfactogustatory Perception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crohn and anti-TNF treatment

Tests at 3 or 4 weeks after the beginning of anti-TNF treatment

triangular test

Intervention Type OTHER

metabolic state, impedance measurement, potential flavours evoked by sucrose,

blood sampling

Intervention Type BIOLOGICAL

sampling of 2 mL

Questionnaires

Intervention Type OTHER

Stunkard, PrefQuest

Crohn and without anti-TNF treatment

tests performed according to patient availability

triangular test

Intervention Type OTHER

metabolic state, impedance measurement, potential flavours evoked by sucrose,

blood sampling

Intervention Type BIOLOGICAL

sampling of 2 mL

Questionnaires

Intervention Type OTHER

Stunkard, PrefQuest

Control

tests performed according to patient availability

triangular test

Intervention Type OTHER

metabolic state, impedance measurement, potential flavours evoked by sucrose,

blood sampling

Intervention Type BIOLOGICAL

sampling of 2 mL

Questionnaires

Intervention Type OTHER

Stunkard, PrefQuest

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

triangular test

metabolic state, impedance measurement, potential flavours evoked by sucrose,

Intervention Type OTHER

blood sampling

sampling of 2 mL

Intervention Type BIOLOGICAL

Questionnaires

Stunkard, PrefQuest

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 60 years,
* Diagnosis of Crohn's disease according to clinical, endoscopic, histological, radiological and biochemical criteria as defined by the European Consensus Conference,
* Men or women who have provided consent and willing to cooperate.


* Adult person
* Without follow-up for a chronic pathology
* Having given its consent

Exclusion Criteria

* Chronic inflammatory intestinal disease (CIID) other than Crohn's disease: haemorrhagic rectocolitis, undetermined colitis, microscopic colitis.
* Intercurrent disease (diabetes and metabolic disease, liver cirrhosis, progressive cancer, acute or chronic infection, Human Immunodeficiency Virus HIV),
* Organ failure (respiratory, heart, or renal failure, neurological disorders),
* Intolerance to gluten,
* Treatments (other than those used for Crohn's disease) able to interfere with food intake,
* Aversion to foods consumed or smelled,
* Poor understanding of cognitive tasks required.
* Crohn's disease complicated by an abscess or infectious complication
* Acute Crohn's disease defined by a CDAI score \> 150

For Controls:


* Protected adult
* Person not affiliated to a social security system
* Pregnant or breastfeeding woman
* Active smoker
* No one who does not speak French
* Taking treatment that interferes with taste or acts on the central nervous system
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire

Dijon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BRONDEL Ass INRA 2011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Autophagy in Paediatric Crohn's Disease
NCT05842564 NOT_YET_RECRUITING NA